These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 39337010)

  • 1. Vamifeport: Monography of the First Oral Ferroportin Inhibitor.
    Pilo F; Angelucci E
    J Clin Med; 2024 Sep; 13(18):. PubMed ID: 39337010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease.
    Nyffenegger N; Zennadi R; Kalleda N; Flace A; Ingoglia G; Buzzi RM; Doucerain C; Buehler PW; Schaer DJ; Dürrenberger F; Manolova V
    Blood; 2022 Aug; 140(7):769-781. PubMed ID: 35714304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
    Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
    Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.
    Kalleda N; Flace A; Altermatt P; Ingoglia G; Doucerain C; Nyffenegger N; Dürrenberger F; Manolova V
    Haematologica; 2023 Oct; 108(10):2703-2714. PubMed ID: 37165842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis.
    Nyffenegger N; Flace A; Varol A; Altermatt P; Doucerain C; Sundstrom H; Dürrenberger F; Manolova V
    Hemasphere; 2024 Sep; 8(9):e147. PubMed ID: 39267817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structures of ferroportin in complex with its specific inhibitor vamifeport.
    Lehmann EF; Liziczai M; Drożdżyk K; Altermatt P; Langini C; Manolova V; Sundstrom H; Dürrenberger F; Dutzler R; Manatschal C
    Elife; 2023 Mar; 12():. PubMed ID: 36943194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does Hepcidin Tuning Have a Role among Emerging Treatments for Thalassemia?
    Longo F; Piga A
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ineffective erythropoiesis and its treatment.
    Cazzola M
    Blood; 2022 Apr; 139(16):2460-2470. PubMed ID: 34932791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepcidin and Anemia: A Tight Relationship.
    Pagani A; Nai A; Silvestri L; Camaschella C
    Front Physiol; 2019; 10():1294. PubMed ID: 31649559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Hepcidin Expression in the Renal Cortex of Sickle Cell Disease Mice.
    Ahmad A; Kumari N; Afangbedji N; Nekhai S; Jerebtsova M
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron dysregulation in beta-thalassemia.
    Leecharoenkiat K; Lithanatudom P; Sornjai W; Smith DR
    Asian Pac J Trop Med; 2016 Nov; 9(11):1035-1043. PubMed ID: 27890361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.
    Saad HKM; Abd Rahman AA; Ab Ghani AS; Taib WRW; Ismail I; Johan MF; Al-Wajeeh AS; Al-Jamal HAN
    Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron and hepcidin: a story of recycling and balance.
    Camaschella C
    Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Lactoferrin Oral Administration in the Treatment of Anemia and Anemia of Inflammation in Pregnant and Non-pregnant Women: An Interventional Study.
    Lepanto MS; Rosa L; Cutone A; Conte MP; Paesano R; Valenti P
    Front Immunol; 2018; 9():2123. PubMed ID: 30298070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepcidin-ferroportin axis in health and disease.
    Ginzburg YZ
    Vitam Horm; 2019; 110():17-45. PubMed ID: 30798811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepcidin and its multiple partners: Complex regulation of iron metabolism in health and disease.
    Ginzburg YZ
    Vitam Horm; 2023; 123():249-284. PubMed ID: 37717987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron metabolism and iron disorders revisited in the hepcidin era.
    Camaschella C; Nai A; Silvestri L
    Haematologica; 2020; 105(2):260-272. PubMed ID: 31949017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.